Nicholas Lydon, Ph.D., FRS is a scientific founder of Blueprint Medicines and has served as a member of our board of directors since April 2011. Dr. Lydon is a co-founder and Chairman of Recludix Pharma Inc. and has served as a member of its board of directors and as a scientific advisor since 2019. Dr. Lydon is a member of VB Therapeutics LLC, which he co-founded in 2019. In addition, Dr. Lydon currently serves as the manager of Staurus Biopharma, LLC, a privately held biopharmaceutical company that he co-founded. Dr. Lydon is a co-founder of AnaptysBio Inc. and served as a scientific advisor and member of its board of directors between 2006 and 2019. From 2003 to 2009, Dr. Lydon served as a scientific advisor and member of the board of directors of Ambit Biosciences Corp., a biopharmaceutical company. From 2000 to 2002, Dr. Lydon served as vice president, small molecule drug discovery, at Amgen, Inc., or Amgen. Prior to joining Amgen, Dr. Lydon founded Kinetix Pharmaceuticals, Inc., or Kinetix, a biotechnology company focused on the discovery and development of selective protein kinase inhibitors, which was acquired by Amgen in 2000, and served as Kinetix’s chief executive officer and as a member of its board of directors. Prior to founding Kinetix, Dr. Lydon worked for Ciba-Giegy AG (now Novartis AG) where he was responsible for the tyrosine protein kinase program, including the discovery and preclinical development of imatinib. Dr. Lydon, has been awarded the Lasker-DeBakey Clinical Medical Research Award, the Kettering Price from the General Motors Cancer Research Foundation and the Japan Prize for his role in the development of imatinib. Dr. Lydon received a B.S. in biochemistry and zoology from the University of Leeds, England, and received a Ph.D. in biochemistry from the Medical Sciences Institute, University of Dundee, Scotland. We believe Dr. Lydon’s detailed knowledge of our company and long tenure with us, having served as one of our scientific founders, along with his experience working with and serving on the boards of directors of life sciences companies and his experience as a senior executive with several life sciences companies qualifies him to serve on our board of director.
What is Nicholas Lydon's net worth?
The estimated net worth of Nicholas Lydon is at least $4.20 million as of September 17th, 2020. Mr. Lydon owns 47,240 shares of Blueprint Medicines stock worth more than $4,199,636 as of April 19th. This net worth evaluation does not reflect any other assets that Mr. Lydon may own. Learn More about Nicholas Lydon's net worth.
How do I contact Nicholas Lydon?
Has Nicholas Lydon been buying or selling shares of Blueprint Medicines?
Nicholas Lydon has not been actively trading shares of Blueprint Medicines during the past quarter. Most recently, Nicholas Lydon sold 500 shares of the business's stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $80.00, for a transaction totalling $40,000.00. Following the completion of the sale, the director now directly owns 47,240 shares of the company's stock, valued at $3,779,200. Learn More on Nicholas Lydon's trading history.
Who are Blueprint Medicines' active insiders?
Blueprint Medicines' insider roster includes Jeffrey Albers (CEO), Percy Carter (Insider), George Demetri (Director), Debra Durso-Bumpus (Insider), Mark Goldberg (Director), Kate Haviland (COO), L. Hewes (Insider), Ariel Hurley (Insider), Michael Landsittel (CFO), Nicholas Lydon (Director), Tracey Mccain (EVP), Christopher Murray (Insider), Fouad Namouni (Insider), Christina Rossi (Insider), and Charles Rowland, Jr. (Director). Learn More on Blueprint Medicines' active insiders.
Are insiders buying or selling shares of Blueprint Medicines?
In the last twelve months, insiders at the biotechnology company sold shares 24 times. They sold a total of 172,543 shares worth more than $13,714,414.59. The most recent insider tranaction occured on March, 28th when CFO Michael Landsittel sold 5,000 shares worth more than $475,000.00. Insiders at Blueprint Medicines own 3.9% of the company.
Learn More about insider trades at Blueprint Medicines. Information on this page was last updated on 3/28/2024.
